bpc 157 human clinical trial evidence safety Here's a nice graphic on BPC-157 that you can hand out to patients who inquire about it. Thanks to Chris Centeno, M.D BPC-157: Experimental Peptide Creates Risk

Why ARA-290 Is Different from Erythropoietin Erythropoietin: Increases red blood cell production Raises hematocrit Increases thrombosis risk at high levels ARA-290: Does not affect red blood cells Does not raise hematocrit Does not increase clotting risk This distinction makes ARA-290 suitable for chronic use in inflammatory and neurologic conditions , where EPO would be unsafe

The possible use has been examined in laboratory and animal research in various physiological systems, such as musculoskeletal, gastrointestinal, and neurological tissues

This evidence gap is the single largest limitation of peptide-based approaches

Methylcobalamin is vitamin B12 in its most natural, active form